Sept 22 (Reuters) - Bausch Health Companies Inc BHC.TO :
* BAUSCH HEALTH AND ALFASIGMA ANNOUNCE RESOLUTION OF XIFAXAN® INTELLECTUAL PROPERTY LITIGATION
* BAUSCH HEALTH COMPANIES INC - SALIX WILL MAINTAIN MARKET EXCLUSIVITY FOR XIFAXAN® (RIFAXIMIN) 200 MG AND 550 MG TABLETS UNTIL 2028
* BAUSCH HEALTH COMPANIES INC - SUN ACKNOWLEDGES VALIDITY OF LICENSED PATENTS WITH RESPECT TO THE TWO XIFAXAN PRODUCTS
* BAUSCH HEALTH - LITIGATION BETWEEN PARTIES RELATED TO XIFAXAN WILL BE DISMISSED, AND ALL INTELLECTUAL PROPERTY PROTECTING XIFAXAN REMAINS INTACT
* BAUSCH HEALTH - SUN WILL HAVE RIGHT TO MARKET ROYALTY-FREE GENERIC VERSIONS OF XIFAXAN 200 MG AND 550 MG TABLETS, SHOULD IT RECEIVE FDA APPROVAL